1 / 9

Increased Regulatory Vigilance with respect to GLP Test Article Characterization

Increased Regulatory Vigilance with respect to GLP Test Article Characterization. George L. DeGeorge, Ph.D., DABT MB Research Laboratories.

fauna
Download Presentation

Increased Regulatory Vigilance with respect to GLP Test Article Characterization

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Increased Regulatory Vigilancewith respect toGLP Test Article Characterization George L. DeGeorge, Ph.D., DABT MB Research Laboratories

  2. Although no Form FDA 483 was issued…our review of the inspection report found that the protocol for study MB 01-XXXX states that test article characterization information is “filed with the sponsor”. While sponsor can maintain such information, you conducted study MB 01-XXXX without obtaining from the Sponsor the necessary characteristics of the test article administered. FDA Follow-up Letter… “Testing facility management must assure that the test articles are appropriately tested for identity, strength, purity, stability, and uniformity, as applicable, …{ 21 CFR 58.31(d) }”

  3. What does 21 CFR 58.31(d) state? • Good Laboratory Practice for Nonclinical Laboratory Studies • Sec. 58.31 Testing facility management • For each nonclinical laboratory study, testing facility management shall: • Designate a study director as described in Sec. 58.33, before the study is initiated. • Replace the study director promptly if it becomes necessary to do so during the conduct of a study. • Assure that there is a quality assurance unit as described in Sec 58.35. • Assure that test and control articles….. (d) Assure that test and control articles or mixtures have been appropriately tested for identity, strength, purity, stability, and uniformity, as applicable.

  4. MB Study Authorization Form • SPONSOR REQUEST: • The sponsor requests that this protocol be implemented: •  As written (or)  Amended per attached description of amendments • Test Article: The test article will be identified in the report and supporting documentation exactly as indicated by the sponsor in section 13.2.1 • Test Article Characterization including identity, strength, stability, solubility, and purity is routinely required in support of data submissions. (EPA 40 CFR 160.105 and 792.105; FDA 21 CFR 58.105, OECD 2.3 -Test and Reference Substances). This information is: •  Attached,  Filed with sponsor  Study will not be submitted to a regulatory agency • Authorization Statement: This protocol is authorized for implementation at MB Research. This study is necessary to estimate any adverse effects of the test compound. To the best of my knowledge and information, this test is not an unnecessary duplication of any previous studies. Study results and reports will be released only to the below named sponsor representative unless other sponsor representatives are identified below. • Test Article Characterization including identity, strength, stability, solubility, and purity is routinely required in support of data submissions. This information is: •  Attached  Filed with sponsor •  Study will not be submitted to a regulatory agency

  5. NEW MB Study Authorization Form • SPONSOR REQUEST: • The sponsor requests that this protocol be implemented: •  As written (or)  Amended per attached description of amendments • Test Article: The test article will be identified in the report and supporting documentation exactly as indicated by the sponsor in section 13.2.1 • Test Article Characterization including identity, strength, stability, solubility, and purity is routinely required in support of data submissions. (EPA 40 CFR 160.105 and 792.105; FDA 21 CFR 58.105, OECD 2.3 -Test and Reference Substances). This information is: •  Attached,  Filed with sponsor  Study will not be submitted to a regulatory agency • Authorization Statement: This protocol is authorized for implementation at MB Research. This study is necessary to estimate any adverse effects of the test compound. To the best of my knowledge and information, this test is not an unnecessary duplication of any previous studies. Study results and reports will be released only to the below named sponsor representative unless other sponsor representatives are identified below. • Test Article Characterization including identity, strength, stability, solubility, and purity is routinely required in support of data submissions. This information is: •  Attached •  Study will not be submitted to a regulatory agency

  6. The final reports prepared at your facility by the study director for study MB 01-XXXX did not include characteristics of the test article. The characteristics of the test article (e.g. purity, strength, and stability) are critical to the study director’s assessment of study outcomes, and the absence of this information does not assure the quality or integrity of the data. FDA Letter (cont.) Test Facility must include characteristics of the test article in the final study report…21 CFR 58.185(a)4 and (a)9…

  7. What does21 CFR 58.185(a)4 and (a)9state? • Good Laboratory Practice for Nonclinical Laboratory Studies • Sec. 58.185 Reporting of nonclinical laboratory study results. • A final report shall be prepared for each nonclinical laboratory study and shall include, but not necessarily be limited to, the following: • Name and address…. • Objectives….. • Statistics…. • The test and… • Stability… • A description… (4) The test and control articles identified by name, chemical abstracts number or code number, strength, purity, and composition or other appropriate characteristics. (9) A description of all circumstances that may have affected the quality or integrity of the data.

  8. Letter to our Sponsors – MBR’s Corrective Action Dear Sponsor: As a follow-up to an FDA GLP inspection conducted earlier this year, MB has been advised by FDA that test article characterization, i.e., identity, strength, purity, composition or other characteristics which define the test article, must be documented for each batch and must be supplied to the study director and included in the final report. Previously, if the characterization was not provided but was filed with the sponsor, the study director did not include an exception to the GLP Compliance Statement. Apparently, this procedure is no longer acceptable to the regulatory authorities. Accordingly, effective immediately, test article characterization must be provided to the study director. In instances where it is not provided, the Compliance Statement will reflect an exception to the GLP requirements, citing the following GLP sections: FDA 21 CFR 58.31(d) and 58.185(a)(4) and (9) (Text attached for your information) EPA 40 CFR FIFRA 160.31(d) and TSCA 792.31(d) (Text is almost identical to FDA) This procedure will be followed for all GLP studies conducted at MB Research. Therefore, the Sponsor Request Form (Sec. 13 of protocol) of all MB protocols has been modified to reflect this new procedure. For your next study, please call me to obtain the revised Sponsor Request Form (Sec. 13 of protocol). As always, MB is committed to providing you with quality, reproducible and scientifically sound studies that comply with GLPs. Should you have any questions or comments, please do not hesitate to contact us. Sincerely,  MB RESEARCH LABORATORIES Previously, if TA characterization was “Filed with the Sponsor”, the Study Director did not include an exception to the GLP Compliance Statement. Apparently, this procedure is no longer acceptable to the regulatory authorities. Effective immediately, TA characterization must be provided to the Study Director. In instances where it is not provided, the Compliance Statement will reflect an exception to the GLP requirements, citing the following GLP sections:21 CFR 58.185(a)(4) and 58.185(a)(9). ….all MB protocols has been modified to reflect this new procedure.

  9. Corrective Action: Revise All Protocols “Test Article Characterization is required in support of data submissions and must be reviewed by the Study Director and included in the final report. (EPA 40 CFR 160.105 and 792.105; FDA 21 CFR 58.105, OECD 6.2). This information is…” BEFORE  Included (or) Filed with Sponsor(or) Not available REVISED:  Included (or) Not available

More Related